Skip to content
Back to Blog
Bio
2025-11-209 min read235

Medical Device Authorization Procedure and Preparation Guide

A detailed guide to the medical device authorization process in Korea, including regulatory requirements and documentation preparation.

KITIM Consulting Team

Medical Device Authorization Procedure and Preparation Guide

Obtaining medical device authorization in Korea requires navigating a structured regulatory framework administered by the Ministry of Food and Drug Safety (MFDS). Understanding the classification system, choosing the appropriate authorization pathway, and preparing comprehensive documentation are essential for a successful submission. This guide provides a detailed overview.

Classification System

Korea classifies medical devices into four classes based on risk level:

  • Class I (lowest risk): Simple devices such as surgical instruments, bandages, and examination gloves. Subject to notification rather than approval
  • Class II (moderate risk): Devices including blood pressure monitors, powered wheelchairs, and ultrasound diagnostic equipment. Require certification by MFDS-recognized bodies
  • Class III (moderate-high risk): Devices such as orthopedic implants, hemodialysis machines, and some in-vitro diagnostics. Require direct MFDS approval
  • Class IV (highest risk): Life-sustaining or high-risk devices including cardiac pacemakers, drug-eluting stents, and some combination products. Require the most extensive MFDS review
  • Classification determines the regulatory pathway, review timeline, and documentation requirements. An incorrect classification can lead to significant delays, so confirming classification through pre-submission consultation with MFDS is recommended.

    Authorization Pathways

  • Notification (Class I): Manufacturers submit a notification to MFDS or a designated body, providing basic product information. Processing typically takes 15-20 business days
  • Certification (Class II): Applications are reviewed by MFDS-recognized certification bodies. The review focuses on technical documentation, performance testing, and quality management system compliance
  • Approval (Class III and IV): Full MFDS review including scientific and clinical assessment. Class IV devices undergo the most rigorous evaluation with advisory committee review when needed
  • Required Documents

    A complete technical file for MFDS submission typically includes:

  • Technical documentation: Product description, design specifications, principles of operation, component materials, and intended use statement
  • Performance testing: Results of bench testing, electrical safety testing (IEC 60601 series for electrical devices), and software validation for software-containing devices
  • Biocompatibility: ISO 10993 biocompatibility test reports for devices contacting the body, with specific test selection based on contact type and duration
  • Clinical data: Clinical evaluation reports based on clinical investigation data, literature review, or equivalence to predicate devices, depending on risk class and novelty
  • Labeling and instructions for use: Korean-language labeling, user manuals, and patient information documents
  • Quality management system: ISO 13485 certification or equivalent quality system documentation
  • MFDS Review Process

    Timeline expectations vary by device class and review pathway:

  • Class I notification: 15-20 business days
  • Class II certification: 60-90 business days
  • Class III approval: 90-120 business days
  • Class IV approval: 120-180 business days
  • Common deficiency letters address issues such as incomplete performance testing data, insufficient clinical evidence for claimed indications, biocompatibility testing gaps, and labeling non-compliance. Responding promptly and thoroughly to deficiency letters is critical, as each round of queries can add weeks to the timeline.

    Post-Market Requirements

    Authorization is only the beginning of regulatory obligations:

  • Vigilance reporting: Manufacturers must report adverse events and device malfunctions to MFDS within prescribed timelines (serious events within 15 days)
  • Periodic safety update reports: Submit regular safety reports summarizing adverse event data, corrective actions, and ongoing safety assessments
  • Quality management: Maintain ISO 13485 compliance and be prepared for periodic MFDS inspections of manufacturing and quality systems
  • Post-market clinical follow-up: For higher-risk devices, conduct planned post-market clinical studies to confirm long-term safety and performance
  • Product changes: Any changes to design, materials, manufacturing, or intended use must be assessed for regulatory impact and may require supplemental submissions
  • How KITIM Can Help

    KITIM guides medical device companies through the entire authorization process, from pre-submission classification consultation to post-market compliance. Our services include regulatory strategy development, technical file preparation, clinical evaluation support, and quality management system consulting. Contact us to discuss your medical device regulatory needs.

    Medical DeviceAuthorizationMFDS

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.